Dr. Rob Koremans has led Teva’s Global Specialty Medicines business as President and CEO since 2013.
A member of Teva’s Executive Committee (TEC), Rob provides input into the overall direction of the Company, and reports to the CEO. He leads an organization of 3000+ employees with 15 direct reports in key leadership positions. Since joining Teva, he has established four global therapeutic areas within Teva’s branded business unit, including CNS, Respiratory, Oncology and Women’s Health.
Rob previously served as President and CEO of Teva Pharmaceuticals Europe beginning in 2012, and established the management structure for branded products in Europe. This included the acquisition of exclusive rights to Copaxone from Sanofi, driving branded product sales which increased by 25%, and the launch of 6 new branded products. In this role, he also focused on the development of PGT, Teva’s joint venture with P&G on its OTC business, achieving 20% growth in sales and operating profit in 2012.
Prior to joining Teva, Rob held senior executive positions at Sanofi, the Elsevier Group, Cryo-Save, Johnson & Johnson (Cilag AG), the Serono Group and Grunenthal GmbH. He received a medical degree from the Erasmus University of Rotterdam in 1988 and earned an executive MBA from Babson College in Massachusetts.
A native of the Netherlands, he is married to a physician and is the father of three daughters. He brings his dedication and commitment as a physician and as business leader to a company that is focused on improving health. In leading his organization, Rob puts the patient at the center, as well as in his life personally.